Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Down 4.5% – Here’s Why

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) dropped 4.5% during trading on Tuesday . The company traded as low as $40.61 and last traded at $41.70. 80,032 shares were traded during trading, a decline of 80% from the average session volume of 392,331 shares. The stock had previously closed at $43.67.

Key Stories Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $65 price target for Eton Pharmaceuticals (ETON). The target implies meaningful upside from recent trading levels and indicates confidence in the company’s longer-term growth prospects.
• Positive Sentiment: The firm expects earnings to strengthen through 2027, forecasting EPS of $0.26 in Q1, $0.30 in Q2, $0.36 in Q3 and $0.35 in Q4. These estimates suggest improving profitability beyond 2026.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The figures appear unreliable or incomplete, so they provide little actionable information about trading sentiment.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to $0.52 from $0.68. Quarterly estimates were also reduced: Q2 EPS to $0.11 from $0.15, Q3 to $0.17 from $0.23 and Q4 to $0.19 from $0.25. The revisions point to weaker-than-previously-expected near-term earnings and may weigh on the shares.
• Negative Sentiment: The updated FY2026 forecast is below the broader consensus estimate of $0.75 per share, increasing the risk of future estimate cuts or earnings-related disappointment.

Wall Street Analysts Forecast Growth

ETON has been the topic of several research analyst reports. Canaccord Genuity Group began coverage on shares of Eton Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $60.00 target price on the stock. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. Finally, HC Wainwright boosted their price objective on shares of Eton Pharmaceuticals from $57.00 to $65.00 and gave the company a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Eton Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Eton Pharmaceuticals Stock Down 1.1%

The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -593.92 and a beta of 0.86. The firm has a 50 day moving average price of $38.23 and a two-hundred day moving average price of $28.20.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The business had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. On average, equities analysts expect that Eton Pharmaceuticals, Inc. will post 0.67 earnings per share for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other news, Director Jennifer Mckie Adams sold 50,000 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Krempa sold 19,679 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13. Following the completion of the transaction, the insider directly owned 25,249 shares in the company, valued at approximately $794,586.03. This represents a 43.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is owned by insiders.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG raised its position in Eton Pharmaceuticals by 4.9% in the fourth quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock valued at $309,000 after purchasing an additional 850 shares during the period. Intech Investment Management LLC boosted its position in shares of Eton Pharmaceuticals by 11.1% in the fourth quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock worth $210,000 after buying an additional 1,244 shares during the period. State of Wyoming boosted its position in shares of Eton Pharmaceuticals by 16.4% in the first quarter. State of Wyoming now owns 9,498 shares of the company’s stock worth $234,000 after buying an additional 1,337 shares during the period. Man Group plc grew its stake in shares of Eton Pharmaceuticals by 6.0% in the second quarter. Man Group plc now owns 23,754 shares of the company’s stock valued at $338,000 after buying an additional 1,350 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Eton Pharmaceuticals in the third quarter valued at about $37,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.